FDA approves Halaven therapy for metastatic late-stage breast cancer

[News]

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

More... (http://www.news-medical.net/news/20101116/FDA-approves-Halaven-therapy-for-metastatic-late-stage-breast-cancer.aspx)